RegeneRx Biopharmaceuticals (RGRX) Stock Overview
A biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
RGRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
RegeneRx Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0005 |
| 52 Week High | US$0.16 |
| 52 Week Low | US$0.0002 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| RGRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 1.1% |
| 1Y | n/a | 34.6% | 28.7% |
Return vs Industry: Insufficient data to determine how RGRX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how RGRX performed against the US Market.
Price Volatility
| RGRX volatility | |
|---|---|
| RGRX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RGRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RGRX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | n/a | J. Finkelstein | www.regenerx.com |
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee’s Pharmaceutical Group for the development and marketing of Tß4-related products; and HLB Therapeutics for the development and marketing of RGN-259, and RGN-137 for dermal wound healing.
RegeneRx Biopharmaceuticals, Inc. Fundamentals Summary
| RGRX fundamental statistics | |
|---|---|
| Market cap | US$754.00 |
| Earnings (TTM) | -US$1.69m |
| Revenue (TTM) | US$76.76k |
Is RGRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGRX income statement (TTM) | |
|---|---|
| Revenue | US$76.76k |
| Cost of Revenue | US$0 |
| Gross Profit | US$76.76k |
| Other Expenses | US$1.77m |
| Earnings | -US$1.69m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did RGRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/24 10:48 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RegeneRx Biopharmaceuticals, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |